Literature DB >> 17287933

Association of bone mineral density and vertebral deformity in patients with rheumatoid arthritis.

Bedriye Mermerci Başkan1, Filiz Sivas, Ebru Alemdaroğlu, Semra Duran, Kürşat Ozoran.   

Abstract

The aim of this study was to investigate the association of vertebral deformities developed as a result of osteoporosis in female patients with rheumatoid arthritis (RA) with bone mineral density (BMD) and disease activity parameters. In the study, 100 female patients with the diagnosis of RA and 56 healthy subjects were recruited. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and rheumatoid factor (RF) tests were performed and the number of swollen and tender joints, level of pain and health assessment questionnaire (HAQ) were recorded in order to evaluate disease activity. Anteroposterior and lateral thoracic and lumbosacral roentgenograms of all patients were taken for radiological examination and deformities of vertebrae were assessed. BMD measurements of patients were performed on vertebrae L1-4 of lumbar region and on total hip, femur neck, trochanter and Ward's triangle of the right side. Vertebral deformity was established in 30% of RA patient group and 7.1% of control group and this was statistically significant. In the statistical analysis, no statistically significant difference was found between BMD measurements of RA and control groups. Patients with RA were divided into two subgroups with regard to using corticosteroids (CS) or not. Vertebral deformity was 32.4% in the subgroup using CS and 24.1% in the subgroup not using CS, and the difference was not statistically significant. There was a correlation between number of deformed joint and age and vertebral deformity incidence. RA is a risk factor on its own for the development of osteoporosis and vertebral deformity and this risk increases by age, excess number of deformed joints and severe course of disease. We think that precautions should be taken immediately to suppress the disease activity as well as to protect the quality and density of bone and to prevent the development of vertebral deformity and fracture while planning the treatment of patients with RA.

Entities:  

Mesh:

Year:  2007        PMID: 17287933     DOI: 10.1007/s00296-007-0323-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Methods to score vertebral deformities in patients with rheumatoid arthritis.

Authors:  W F Lems; Z N Jahangier; J A Raymakers; J W Jacobs; J W Bijlsma
Journal:  Br J Rheumatol       Date:  1997-02

2.  Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis.

Authors:  R N de Nijs; J W Jacobs; J W Bijlsma; W F Lems; R F Laan; H H Houben; E J ter Borg; A M Huisman; G A Bruyn; P L van Oijen; A A Westgeest; A Algra; D M Hofman
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

3.  Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group.

Authors:  A A Ismail; C Cooper; D Felsenberg; J Varlow; J A Kanis; A J Silman; T W O'Neill
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

4.  Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register.

Authors:  G Haugeberg; R E Ørstavik; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

5.  Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis.

Authors:  B J Harrison; C E Hutchinson; J Adams; I N Bruce; A L Herrick
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

6.  Quantitative ultrasound and bone mineral density: discriminatory ability in patients with rheumatoid arthritis and controls with and without vertebral deformities.

Authors:  R E Ørstavik; G Haugeberg; T Uhlig; P Mowinckel; T K Kvien; J A Falch; J I Halse
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

7.  Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry.

Authors:  Ragnhild E Orstavik; Glenn Haugeberg; Till Uhlig; Petter Mowinckel; Jan A Falch; Johan I Halse; Tore K Kvien
Journal:  Osteoporos Int       Date:  2004-06-12       Impact factor: 4.507

8.  Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women.

Authors:  Kristina Forslind; Catharina Keller; Björn Svensson; Ingiäld Hafström
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

Review 9.  Effects of rheumatoid arthritis on bone.

Authors:  Glenn Haugeberg; Ragnhild E Ørstavik; Tore K Kvien
Journal:  Curr Opin Rheumatol       Date:  2003-07       Impact factor: 5.006

10.  Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

Authors:  N F Peel; D J Moore; N A Barrington; D E Bax; R Eastell
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

View more
  9 in total

1.  Morphological and volumetric analysis of the development of atlantoaxial vertical subluxation in rheumatoid arthritis.

Authors:  Toshiyuki Dokai; Hideki Nagashima; Toru Okano; Yoshiro Nanjo; Yuji Kishimoto; Atsushi Tanida; Suguru Kakite; Hiroshi Hagino
Journal:  Yonago Acta Med       Date:  2013-03-01       Impact factor: 1.641

2.  Perforation rates of cervical pedicle screw insertion by disease and vertebral level.

Authors:  Masashi Uehara; Jun Takahashi; Hiroki Hirabayashi; Hiroyuki Hashidate; Nobuhide Ogihara; Keijiro Mukaiyama; Shota Ikegami; Hiroyuki Kato
Journal:  Open Orthop J       Date:  2010-03-04

3.  Prevalence and risk factors associated with low-impact fractures in men with rheumatoid arthritis.

Authors:  José Carlos Amaral Filho; Marcelo Medeiros Pinheiro; Charlles Heldan de Moura Castro; Vera Lúcia Szejnfeld
Journal:  Clin Rheumatol       Date:  2013-11-14       Impact factor: 2.980

4.  Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients.

Authors:  Yasunori Omata; Futoshi Hagiwara; Jinju Nishino; Ko Matsudaira; Yuho Kadono; Takuo Juji; Toshihito Mori; Hisanori Nakayama; Yuichi Nagase; Jun Hirose; Tetsuro Yasui; Takumi Matsumoto; Toshihiro Matsui; Shigeto Tohma; Sakae Tanaka
Journal:  J Bone Miner Metab       Date:  2013-12-21       Impact factor: 2.626

5.  Skeletal health among African Americans with recent-onset rheumatoid arthritis.

Authors:  J R Curtis; T Arora; M Donaldson; G S Alarcón; L F Callahan; L W Moreland; S L Bridges; T R Mikuls
Journal:  Arthritis Rheum       Date:  2009-10-15

6.  Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis.

Authors:  Linda Dirven; M van den Broek; J H L M van Groenendael; W M de Beus; P J S M Kerstens; T W J Huizinga; C F Allaart; W F Lems
Journal:  BMC Musculoskelet Disord       Date:  2012-07-23       Impact factor: 2.362

7.  The risk of osteoporotic fractures according to the FRAX model in Korean patients with rheumatoid arthritis.

Authors:  Jae Ho Lee; Young Sun Suh; Jung Hee Koh; Seung-Min Jung; Jennifer Jooha Lee; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

Review 8.  A review of the use of dual-energy X-ray absorptiometry (DXA) in rheumatology.

Authors:  S Bobo Tanner; Charles F Moore
Journal:  Open Access Rheumatol       Date:  2012-12-11

Review 9.  A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis population.

Authors:  D E Robinson; E M Dennison; C Cooper; T P van Staa; W G Dixon
Journal:  Bone       Date:  2016-06-03       Impact factor: 4.398

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.